Quest Diagnostics Incorporated has announced strong financial results for the third quarter of 2026, showcasing a significant revenue increase and an upward revision of its full-year guidance. The company's performance reflects a growing demand for diagnostic services, driven by advancements in technology and an aging population.
On October 22, 2026, Quest Diagnostics reported third-quarter revenues of $3.10 billion, marking a 10% increase from the previous year. The company also reported diluted earnings per share (EPS) of $2.78, up 28.7% year-over-year, and an adjusted diluted EPS of $3.00, which is a 15.4% increase from 2025. These results prompted Quest to raise its full-year revenue guidance to between $12.065 billion and $12.105 billion, with diluted EPS expectations now between $10.21 and $10.31.
Quest Diagnostics, a leading provider of diagnostic information services, operates under the Standard Industrial Classification (SIC) code 8071, which pertains to services in medical laboratories. The company is traded on the New York Stock Exchange under the ticker symbol DGX. Recent filings indicate that the company has been actively engaging in strategic initiatives, including the acquisition of outreach lab assets and the expansion of its test offerings.
The filing reveals that the company is capitalizing on strong organic growth across various channels, including physician, hospital, and consumer segments. Jim Davis, Chairman and CEO, stated, “We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital, and consumer channels, complemented by productivity gains from automation and AI.”
In addition to financial performance, Quest Diagnostics has been innovating its service offerings. The company announced a new feature allowing iPhone and iPad users to purchase tailored laboratory test panels directly through the Apple Health app, enhancing accessibility for consumers. Furthermore, Quest has finalized agreements to acquire lab assets from a leading health system, demonstrating its commitment to expanding its operational footprint.
Looking ahead, Quest Diagnostics is set to hold its 2027 Investor Day on March 25, 2027, at the New York Stock Exchange, where it will likely provide further insights into its strategic direction and growth initiatives. This event will be an opportunity for investors to engage with the company and understand its plans for the future.
The recent performance of Quest Diagnostics may have implications for its competitors in the medical laboratory sector. As the company continues to innovate and expand its services, other players in the industry may need to adapt their strategies to remain competitive. The filing, accession number 0001022079-26-000097, indicates a robust outlook for Quest Diagnostics, solidifying its position as a leader in the diagnostic services market.